

Marrone Bio Innovations

12:59 09 Dec 2019

Marrone Bio's biology-based seed treatments in Europe improved yields, cost effectively controlled soil insects

Marrone Bio Innovations Inc (NASDAQ:MBII) announced Monday that its field trial results for biology-based seed treatments in Europe demonstrated improved yields and cost-effective control of soil insects and nematodes that are equivalent to or better than current industry standards.

Additionally, the company said its wholly-owned subsidiary, Pro Farm Technology OY (Pro Farm), has demonstrated significant benefits to growers when its patented Foramin nutrient technology is used in conjunction with conventional or biology-based seed treatments.

Foramin offers growers enhanced plant physiology, reduced plant stress, and improved yields and crop quality.

READ: Marrone Bio's founder Dr Pamela Marrone to step down as CEO
Results from recent yield and stress tolerance trials will be presented by Kalle Virta, director of research and development for Pro Farm, at the "Exceed The Seed" event during the American Seed Trade Association meeting on Monday in Chicago.

"The past growing season marked our first international tests — including in the European Union — of the Marrone Bio suite of seed- and soil-applied products," said Chief Commercial Officer Kevin Hammill. "These bioprotection products complement Pro Farm's existing portfolio of plant health products. With Pro Farm's broad international distribution capabilities, we expect to bring to more growers the benefits of MBI's technology and broad bioprotection product portfolio."

Marrone Bio's and Pro Farm's family of seed and soil treatment products are currently available to growers through its distribution and seed company partners in the US, Canada, Uruguay and Europe with near-term expansion into India, Australia, Brazil, Argentina, Paraguay, Bolivia and CIS (Commonwealth of Independent States) region for use in a wide variety of crops including corn, soybean, cotton, wheat, barley, sunflower, oilseed rape and vegetables.

MBI European Seed Treatment Field Trial Results

Corn seed treatment trials testing MBI-203 and MBI-206 for corn root worm and nematode control showed yield gains against both the untreated control and a currently used chemical option. When compared with the current treatment, yield gains as high as 35% were observed when used at commercial application rates.


Pro Farm Stress-Tolerance Greenhouse and Field Trial Results

Pro Farm tested its Foramin products for 18 different stress parameters across multiple growth stages for barley and wheat in both greenhouse and field conditions in Europe throughout 2019. Foramin is designed to be used in combination with a standard conventional seed treatment package. The Foramin products include both a seed

Price: 0.6501

Market Cap: \$94.61 m

1 Year Share Price Graph



April 2019 October 2019 April 2020

Share Information

Code: MBII

Listing: NASDAQ

52 week	High	Low
	1.91	0.6301

Sector: Agribusiness

Website:
www.marronebioinnovations.com

Company Synopsis:

Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth company leading the movement to move a sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment that help customers operate more sustainably while increasing their return on investment.

action@proactiveinvestors.com

treatment and a foliar-applied product.

Meanwhile, Marrone Bio also said last season's results from barley and wheat field trials in Latin America showed yield increases in barley ranging from 2.1% to 6.7%; and in wheat from 9% to 14.3%. At current commodity prices, these yield gains would add approximately \$8 to \$26 per acre in revenue for barley growers, and approximately \$44 to \$68 per acre in revenue for wheat growers.

Marrone Bio, based in Davis, California, provides bio-based pest management and plant health products for the US and international agricultural and water markets. Boasting a portfolio of over 400 current and pending patents, the company's products include Regalia, Stargus, Grandevo, Venerate, Majestene, Haven and Jet Oxide; in addition to these offerings, the company is also formulating another bioherbicide and biofumigant.

The company's stock recently traded up more than 7% to \$1.28 a share in New York.

--ADDS share price--

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Marrone Bio Innovations named herein, including the promotion by the Company of Marrone Bio Innovations in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).